Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.

ABSTRACT:

Background

Increased breast cancer screening over the past four decades has led to a substantial rise in the diagnosis of ductal carcinoma in situ (DCIS). Although DCIS lesions precede invasive ductal carcinoma (IDC), they do not always transform into cancer. The current standard-of-care for DCIS is an aggressive course of therapy to prevent invasive and metastatic disease resulting in over-diagnosis and over-treatment. Thus, there is a critical need to identify functional determinants of progression of DCIS to IDC to allow discrimination between indolent and aggressive disease. Recent studies show that super-enhancers, in addition to promoting other gene transcription, are themselves transcribed producing super-enhancer associated long noncoding RNAs (SE-lncRNAs). These SE-lncRNAs

SUBMITTER: Ropri AS 

PROVIDER: S-EPMC8557595 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature